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The leukocyte adhesion to endothelium is pivotal in leukocyte 
recruitment which takes place during inflammatory, auto-
immune and infectious conditions. The interaction between 
leukocytes and endothelium requires an array of adhesion 
molecules expressed on leukocytes and endothelial cells, 
thereby promoting leukocyte recruitment into sites of in-
flammation and tissue injury. Intervention with the adhesion 
molecules provides a platform for development of anti-in-
flammatory therapeutics. This review will focus on devel-
opmental endothelial locus-1 (Del-1), an endogenous in-
hibitor of leukocyte adhesion. 
[Immune Network 2009;9(5):153-157]
INTRODUCTION
Leukocyte-endothelial Interactions
Leukocytes circulating in the blood need to migrate into tis-
sues where a pathogen- or nonpathogen-derived antigen or 
inflammation is present. In particular, leukocyte recruitment 
is  pivotal  during  infection  caused  by  bacterial,  viral,  fungal 
or parasitic pathogens, during inflammatory disorders, and in 
the course of autoimmune diseases. All leukocytes participat-
ing in innate or adaptive immunity have the ability to migrate 
to the sites of inflammation or tissue injury by crossing endo-
thelial barriers between blood and tissues (1,2). The process 
of leukocyte recruitment comprises a tightly regulated cascade 
of adhesive interactions between leukocytes and endothelial 
cells; (i) leukocyte capture by activated endothelium, (ii) leu-
kocyte rolling on the endothelium, (iii) slow rolling of leuko-
cytes on the endothelium, (iv) leukocyte activation by chemo-
kines on the endothelium, (v) firm adhesion of leukocytes on-
to the endothelium, (vi) post-adhesion leukocyte crawling or 
locomotion,  and  (vii)  transendothelial  migration  or  diape-
desis. Distinct families of adhesion molecules control which 
c e l l s  a r e  t o  b e  c o r r e c t l y  r e c r u i t e d  t o  t h e  r i g h t  p l a c e  a t  t h e  
right  time  (Fig.  1)  (3,4).
ADHESION MOLECULES THAT REGULATE LEUKOCYTE- 
ENDOTHELIAL INTERACTIONS
At sites of inflammation, the endothelium is locally activated 
by cytokines to express adhesion molecules called selectins 
on  its  surface  where  the  leukocytes  are  captured  from  the 
blood and start rolling along the endothelial surface, which 
is  the  initial  step  of  the  leukocyte-endothelial  interactions. 
Capturing  and  rolling  are  primarily  mediated  by  the  inter-
action  between  endothelial  selectins  and  their  glycosylated 
leukocyte selectin ligands. Under certain circumstances, how-
ever,  capturing  and  rolling  are  mediated  by  the  interaction 
between  leukocyte  integrins  α 4β 1  (VLA-4)  and  α 4β 7 a n d  
their  endothelial  ligands  VCAM-1  and  MadCAM-1,  both  of 
which  are  members  of  immunoglobulin  superfamily  (5-9).
    The leukocyte rolling on the vessel wall allows the inter-
action of G-protein coupled receptors (GPCRs) on the leuko-
cyte surface with the specific chemokines which are clustered 
and immobilized via binding to glycosaminoglycans in the en-
dothelial  glycocalyx,  thereby  priming  the  GPCRs  (10-12). 
Activation of the GPCRs triggers an inside-out signaling cas-
cade which induces integrin clustering at contact site and rap-
id conformational change in integrins to an active state. This 
allows efficient binding of leukocyte  β1  and β2  integrins, 
i.e., LFA-1, Mac-1 or VLA-4, to immunoglobulin superfamily 
receptors, ICAM-1, -2 or VCAM-1, on the endothelium, result-
ing in leukocyte arrest and firm adhesion to the vessel wall Del-1 is a Leukocyte Adhesion Inhibitor
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Figure 1. A schematic diagram of the 
process of leukocyte recruitment.
( 1 3 , 1 4 ) .  S e l e c t i n - m e d i a t e d  i n i t i a l  l e u k o c y t e  r o l l i n g  a n d  s u b -
sequent integrin activation may also cooperate to mediate an 
additional step termed slow rolling prior to the step of firm 
adhesion  (8,15).
    Once firmly adhered, leukocytes crawl or locomote along 
the endothelial surface to find a junction between two endo-
thelial  cells  (paracellular  route)  or  to  find  a  way  to  pass 
through one endothelial cell (transcellular route). Formation 
of transmigratory cups by leukocyte integrin LFA-1 and its en-
dothelial ligand ICAM-1 is essential in both paracellular and 
transcellular routes (16-19). Ligation of ICAM-1 by leukocyte 
integrins, followed by intracellular signaling events, opens up 
endothelial  junctions  (20-23).  Transmigration  of  leukocytes 
through the endothelial layer is achieved by a chain of adhe-
sive events which are orchestrated by a number of adhesion 
molecules.  Several  homophilic  and  heterophilic  interactions 
between the leukocyte/endothelial apical and junctional ad-
hesion molecules take place sequentially (24-26). Molecules 
directly  acting  in  the  transmigration  include  leukocyte  in-
tegrins,  endothelial  immunoglobulin  superfamily  members 
(ICAM-1,  -2,  JAM-A,  -B,  -C  and  PECAM-1)  and  a  non-im-
munoglobulin  molecule  CD99  (27-31).
    The  aforementioned  classical  leukocyte-endothelial  inter-
actions  in  the  leukocyte  recruitment  do  not  occur  in  all 
tissues.  Non-classical  leukocyte  endothelial  interactions  are 
regulated by the tissue-specific microvasculature environment 
with  unusual  combinations  of  distinct  endothelial  adhesion 
molecules and chemokines, and tissue-specific signaling path-
ways (32-35). For example, leukocyte migration to the liver 
primarily takes place in the hepatic sinusoids, not in the post-
capillary venules as is the case with many other tissues. As 
the hepatic sinusoids have non-classical endothelial adhesion 
molecules and a set of unique predominant chemokines on 
the vascular endothelium, unusual leukocyte adhesion mole-
cules  are  employed  (33,35-37).
    Although immune cell migration is critical for protective im-
mune responses against pathogens, the accumulation of leu-
kocytes in the tissues could trigger significant release of cyto-
toxic  mediators  from  leukocytes,  leading  to  tissue  damage 
and  finally  a  wide  spectrum  of  inflammatory  conditions. 
Thus, inhibition of excessive or misdirected leukocyte recruit-
ment  provides  a  means  for  anti-inflammatory  therapeutics. 
DEVELOPMENTAL ENDOTHELIAL LOCUS-1 (DEL-1): 
STRUCTURE AND EXPRESSION
Del-1 (also termed Edil3) is a 52 kDa glycoprotein secreted 
by endothelial cells and associates with the endothelial cell Del-1 is a Leukocyte Adhesion Inhibitor
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Figure 2. A domain structure of Del-1.
surface  and  extracellular  matrix,  but  seems  not  to  circulate 
in the blood (38-40) (Choi unpublished). Human Del-1 shares 
more  than  97%  amino  acid  identity  with  the  mouse 
counterpart. Del-1 consists of a signal sequence at its N-termi-
n u s ,  t h r e e  e p i d e r m a l  g r o w t h  f a c t o r  ( E G F ) - l i k e  r e p e a t s  a n d  
two discoidin I-like domains at its C-terminus (Fig. 2) (40). 
It has been shown that the discoidin domains are responsible 
for  binding  to  sulfated  glycan  and  phosphatidyl  serine-rich 
membrane (39,40). On the other hand, the second EGF like 
r e p e a t  c o n t a i n s  a n  A r g - G l y - A s p  ( R G D )  m o t i f  t h a t  e n a b l e s  
Del-1 to bind integrin α vβ 3, mediating adhesion of endothe-
lial  cells  to  Del-1  (40).
    Expression  of  Del-1  was  initially  observed  in  embryonic 
cells  including  endothelium  and  thymus,  and  subsequent 
studies showed its expression in adult endothelial cells, some 
subsets  of  macrophages  and  hypertrophic  chondrocytes,  It 
was  recently  reported,  however,  that  Del-1  is  expressed  in 
adult mice in a tissue-specific manner: strong expression in 
the lung, brain and eye, a very little in the kidney, and none 
in the intestine, liver, heart, spleen, whole blood and bone 
m a r r o w  c e l l s  ( 3 8 ) .
INHIBITION OF LEUKOCYTE-ENDOTHELIAL INTER-
ACTION BY DEL-1
A role for Del-1 may be inferred from its expression in adult 
vascular  endothelium.  Recently,  it  was  demonstrated  that 
Del-1 functions as an endogenous inhibitor of a major leuko-
cyte adhesion receptor LFA-1 to prevent leukocyte adhesion 
to the endothelium (38). Unlike many adhesion molecules in-
cluding selectins and Ig superfamily members promoting leu-
kocyte adhesion on the endothelium, Del-1 inhibits the proc-
e s s  o f  l e u k o c y t e  b i n d i n g  t o  t h e  e n d o t h e l i u m ,  t h e r e b y  s u p -
pressing  entrance  of  leukocytes  to  inflamed  tissues.
  D e l - 1 ’s loss of function phenotype is characterized by an 
increase in leukocyte adhesion on the vascular endothelium 
and increased inflammatory cell recruitment. Del-1 deficient 
mice showed more leukocytes adhering on the post-capillary 
vasculature  under  both  non-inflamed  and  inflamed  con-
ditions, than wild type mice, as demonstrated by intravital mi-
croscopy (38). Increased adhesion of leukocytes to the vas-
cular endothelium was a prelude to an increase in leukocyte 
migration  into  the  inflamed  tissue.  Intranasal  administration 
of  LPS  to  the  Del-1  deficient  mice  to  induce  lung  in-
flammation  yielded  more  neutrophil  accumulation  in  bron-
choalveolar  lavage  fluid,  as  opposed  to  control  mice  (38). 
This  phenotype  was  reversed  by  the  absence  of  LFA-1  on 
leukocytes. Upon LPS-elicited lung inflammation, LFA-1/Del-1 
double deficient mice display very low leukocyte recruitment, 
indicating that the phenotype of Del-1 deficiency is depend-
ent  on  the  presence  of  LFA-1  (38).
    Given that Del-1 is a ligand for LFA-1, it is intriguing that 
Del-1 inhibits the function of LFA-1 (38). Other LFA-1 ligands 
including ICAM-1 are known to enhance leukocyte adhesion. 
However, Del-1 is an exception. Under physiologic flow con-
ditions, addition of Del-1 to the system where leukocytes ad-
here onto immobilized ICAM-1 via interaction with activated 
LFA-1 represses the adhesion of leukocytes (38). This implies 
t h a t  D e l - 1  m a y  c o m p e t e  w i t h  I C A M - 1  f o r  t h e  b i n d i n g  t o  
LFA-1.  Studies  on  the  mechanism  by  which  Del-1  inhibits 
LFA-1  functions  are  underway.
    Del-1-mediated inhibition of the interaction between LFA-1 
and  ICAM-1  further  implies  that  Del-1  could  be  used  as  a 
therapeutic tool for inflammatory diseases. In such a case, a 
f air  am ou n t of  ex o g e no u s D e l- 1 i s w o rt h t o  e mp lo y,  g i ve n 
that ICAM-1 is up-regulated in the tissues during the course 
of  inflammation.  Following  LPS-elicited  lung  inflammation, 
Del-1  deficient  mice  supplemented  with  soluble  Del-1  be-
haved in a comparable fashion to the wild type mice in terms 
of  inflammatory  cell  recruitment  into  the  lung  tissues,  re-
capitulating  Del-1’s  potential  as  anti-inflammatory  ther-
apeutics  (38).
    Modulation of Del-1 expression could also represent a can-
didate  therapeutic  strategy  for  autoimmune  and  chronic  in-
f l a m m a t o r y  d i s e a s e .  D e l - 1  m R N A  m e s s a g e  w a s  d o w n - r e g u -
lated in the inflamed tissues and the endothelial cells upon 
induction  of  inflammation  by  TNF-α  stimulation  (38).  It  is 
reasonable therefore that as a resident anti-inflammatory mol-
ecule, such a decrease in Del-1 expression may render the 
body’s normal inflammatory response more competent. It is 
tempting  to  speculate  that  constitutively  expressed  Del-1  in 
certain tissues may function as a gate keeper within the tis-
sues against unspecified potential weak inflammatory agents. 
As  a  result,  normal  healthy  subjects  should  not  respond  to 
the  agents,  thereby  preventing  the  initiation  of  immune 
response.  However,  those  who  have  defects  in  the  ex-Del-1 is a Leukocyte Adhesion Inhibitor
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pression and/or function of Del-1 may show hypersensitivity. 
Taken together, Del-1 holds promise for treating diseases re-
lated  to  excessive  or  deficient  recruitment  of  leukocytes.  If 
excessive recruitment is required (i.e., infectious disease), a 
strategy to inhibit Del-1 should be applied. Conversely, if ex-
cessive  leukocyte  is  the  culprit,  a  strategy  to  boost  Del-1 
should  be  applied.
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